Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Primary Chemotherapy With Non-pegylated Liposomal Doxorubicin, Paclitaxel and Lapatinib in Patients With HER2-positive Early

NCT01172223 is registered in ClinicalTrials.gov with Prof Dirk Elling as lead sponsor.

NCT NCT01172223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01172223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Primary Chemotherapy With Non-pegylated Liposomal Doxorubicin, Paclitaxel and Lapatinib in Patients With HER2-positive Early
Lead sponsor
Prof Dirk Elling
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2007
Completion date
December 31, 2013
Enrollment
81 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer